IJFANS International Journal of Food and Nutritional Sciences

ISSN PRINT 2319 1775 Online 2320-7876

Clinical Pharmacology for New-Borns

Main Article Content

Dr. Jyotsna Sharma1*, Dr. Shaktibala Dutta2 , Dr. Vaishali Lote3

Abstract

Neonatal medication administration should be based on an integrated understanding of the developing physiological characteristics of the newborn receiving the medicine as well as the pharmacokinetics (PK) and pharmacodynamics (PD) of a specific drug. Because of this, neonatal clinical pharmacology is as dynamic and varied as the neonates we admit to our units, and the factors that account for the variability are at least as important as median estimates. Given the risks of extrapolating maturational drug clearance solely based on "adult" metabolism, the special circumstances of neonatal clinical pharmacology will be underlined (propofol, paracetamol). Furthermore, not all maturational processes progress at the same rate. The distinctions between hepatic and renal maturation will be used to highlight this (tramadol, morphine, midazolam). Finally, pharmacogenetics should be customised for newborns rather than simply reflecting adult notions. Due to this variability, neonatal clinical pharmacology clinical research is desperately needed, and PK/PD modelling can help with this. Furthermore, pharmacovigilance is required to identify specific adverse effects regardless of the evidence that is currently available to guide medication. Therefore, paediatric anesthesiologists ought to think about making a contribution to better pharmacotherapy by working together on clinical trial design and reporting on side effects of certain medications.

Article Details